Literature DB >> 18088016

Hymenoptera venom allergy: taking the sting out of difficult cases.

D G Ebo1, M M Hagendorens, C H Bridts, L S De Clerck, W J Stevens.   

Abstract

BACKGROUND: Correct identification of the culprit venom is a prerequisite for specific venom immunotherapy.
OBJECTIVE: To assess whether the basophil activation test (BAT) constitutes an additional diagnostic instrument in patients with equivocal or negative specific immunoglobulin (Ig) E or venom skin test (VST) results.
METHODS: One hundred eighteen patients with a compelling history of IgE-mediated hymenoptera venom allergy were enrolled. Venom-specific IgE was quantified by ImmunoCAP and VST was performed in all patients. Basophil activation was analyzed by flow cytometry after labeling with anti-IgE and anti-CD63.
RESULTS: In 64 out of 118 patients, diagnosis was considered as definite and the entomologic description was confirmed by unequivocal and concordant positive specific IgE and VST results. In 53 of those 64 patients, BAT confirmed diagnosis, whereas the remaining 11 patients were nonresponsive in the BAT analysis. Forty-seven patients (40%) had a tentative diagnosis of venom allergy, as they had divergent specific IgE or VST results. In 31 of those patients, BAT was positive only for the suspected venom and helped to establish diagnosis of wasp and honeybee venom allergy in 28 and 3 patients, respectively. BAT was diagnostic in 7 patients with complete negative results for specific IgE and VST, despite clear entomologic identification.
CONCLUSIONS: In about half the patients with diagnosis of venom allergy, unequivocal specific IgE and VST results are obtained and additional tests are not needed. In the remainder, diagnosis is less straightforward due to discrepant or negative specific IgE orVST results. In these patients, BAT constitutes a helpful additional instrument to identify the culprit venom and start venom immunotherapy accordingly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18088016

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  7 in total

1.  [Cellular in-vitro assays. Applicability in daily routine].

Authors:  B Wedi; A Kapp
Journal:  Hautarzt       Date:  2010-11       Impact factor: 0.751

2.  Basophil sensitivity through CD63 or CD203c is a functional measure for specific immunotherapy.

Authors:  Susan Mikkelsen; Bo Martin Bibby; Mette Konow Bøgebjerg Dolberg; Ronald Dahl; Hans Jürgen Hoffmann
Journal:  Clin Mol Allergy       Date:  2010-02-16

Review 3.  Update on the performance and application of basophil activation tests.

Authors:  Emily C McGowan; Sarbjit Saini
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

4.  Inconsistent results of diagnostic tools hamper the differentiation between bee and vespid venom allergy.

Authors:  Gunter J Sturm; Chunsheng Jin; Bettina Kranzelbinder; Wolfgang Hemmer; Eva M Sturm; Antonia Griesbacher; Akos Heinemann; Jutta Vollmann; Friedrich Altmann; Karl Crailsheim; Margarete Focke; Werner Aberer
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

5.  Basophil activation test compared to skin prick test and fluorescence enzyme immunoassay for aeroallergen-specific Immunoglobulin-E.

Authors:  Faisal M Khan; Aito Ueno-Yamanouchi; Bazir Serushago; Tom Bowen; Andrew W Lyon; Cathy Lu; Jan Storek
Journal:  Allergy Asthma Clin Immunol       Date:  2012-01-20       Impact factor: 3.406

6.  Importance of basophil activation testing in insect venom allergy.

Authors:  Mitja Kosnik; Peter Korosec
Journal:  Allergy Asthma Clin Immunol       Date:  2009-12-01       Impact factor: 3.406

7.  Short-, Intermediate-, and Long-Term Changes in Basophil Reactivity Induced by Venom Immunotherapy.

Authors:  Ana Rodríguez Trabado; Carmen Cámara Hijón; Alfonso Ramos Cantariño; Silvia Romero-Chala; José Antonio García-Trujillo; Luis Miguel Fernández Pereira
Journal:  Allergy Asthma Immunol Res       Date:  2016-09       Impact factor: 5.764

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.